The read at a glance
Computed from the FY2025 annual filing. Full history and the components behind each score are in the app.
- Distress risk · Altman Z-Score -28.17 — distress zone — historically elevated failure riskWatch
- Earnings-manipulation signal · Beneish M 19.13 — flag raised, worth a closer lookWatch
- Earnings quality 63/100 — worth a closer lookWatch
Where the revenue comes from
Fiscal 2025, as RenovoRx, Inc. reports it. History and quarterly detail are in the app.
- All Other Segments$1.1M
Leadership changes
From RenovoRx, Inc.'s own filings, the day they're filed.
- Ramtin Agah · Chief Medical Officer · appointmenteff. 2026-02-27
- Mark Voll · Chief Financial Officer · appointmenteff. 2026-02-04
- Qualified Termination · President · departureeff. 2026-02-04
Latest filings
- 10-Q · Quarterly report2026-05-14
- 8-K · Company announcement2026-05-14
- DEF 14A · Annual proxy (pay & governance)2026-04-30
- 8-K · Company announcement2026-03-30
- 10-K · Annual report2026-03-30
In the full recordFree for 14 days
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, every figure source-linked🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask anything about RenovoRx, Inc., every answer cited🔒
- The Intelligence Brief — added when RenovoRx, Inc.'s brief passes our SEC-figure check🔒
Every figure links to the filing it came from, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.